CAMBRIDGE, Mass. & CINCINNATI--(BUSINESS WIRE)--Akebia Therapeutics, a leader in the development of hypoxia-inducible factor (HIF) inhibitors as therapeutic advances for patients with serious diseases ...
Amello says working in healthcare gives him the opportunity to affect people's lives in a profound way. As a young man, Jason Amello wanted to be a musician, because he likes how music can reach and ...
(RTTNews) - TScan Therapeutics, Inc. (TCRX) on Monday announced the appointment of Jason A. Amello as its Chief Financial Officer. Gavin MacBeath, Ph.D., Chief Executive Officer, expressed confidence ...
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...
Jason Amello's most active month to dispose stocks was the month of March. 2017 saw Jason Amello paying a total of $481,650.00 for 86,500 shares, this is the most they've acquired in one year. In 2011 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback